Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Abstract excerpt

RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis. Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years due to its essential role in tumor formation and maintenance. Yet the quest to inhibit this challenging foe has been elusive. Although once considered "undruggable", the struggle to directly inhibit RAS has seen recent success with the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allosteric Regulation
• Share to Alternative Splicing
• Share to Antibodies, Monoclonal